"Curium™ announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for BEXLUTRY™ lutetium Lu 177 dotatate injection for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults."
Framing: assertive ·
First seen: 2026-09-15 ·
Last seen: 2026-09-15 ·
Spread: 1 articles
The Aporia